Stoke Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-6.89	-88.98	-104.7	-101.07	-85.81
Depreciation & Amortization	1.77	2.18	2.47	1.55	0.97
Stock-Based Compensation	32.24	27.47	25.26	22.85	16.45
Other Adjustments	2.12	0.62	1.94	1.78	1.43
Change in Receivables	-4.27	-0.05	-	-	-
Changes in Accounts Payable	21.29	3.09	-3.21	-3.53	2.9
Changes in Unearned Revenue	-0.13	-29.39	-3.35	51.74	-
Changes in Other Operating Activities	-0.55	-1.79	0.53	-5.18	-2.85
Operating Cash Flow	45.59	-86.85	-81.07	-31.87	-66.91
Capital Expenditures	-0.67	-0.2	-1.62	-3.96	-1.2
Purchases of Investments	-322.72	-167.27	-	-201.32	-87.23
Proceeds from Sale of Investments	136.58	60	107.56	159.4	12
Investing Cash Flow	-186.81	-107.48	105.95	-45.88	-76.43
Issuance of Common Stock	97.39	131.09	53.01	46.41	1.29
Net Common Stock Issued (Repurchased)	97.39	131.09	53.01	46.41	1.29
Other Financing Activities	-	-	-	0	-0
Financing Cash Flow	97.39	131.09	53.01	46.41	1.28
Net Cash Flow	-43.84	-63.23	77.89	-31.34	-142.05
Free Cash Flow	44.92	-87.05	-82.68	-35.83	-68.11
FCF Margin	24.35%	-238.15%	-941.72%	-288.82%	-
Free Cash Flow Per Share	0.76	-1.61	-1.88	-0.92	-1.85
Levered Free Cash Flow	14.83	-115.1	-109.88	-60.46	-85.99
Unlevered Free Cash Flow	1.12	-127.49	-119.95	-63.75	-86.25

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q